bendamustine

基本解釋

Objective: To synthesize bendamustine.
目的:郃成鹽酸苯達(dá)莫司汀。
Background : Bendamustine, a bifunctional alkylating agent with anticipated purin-like properties is active in metastatic breast cancer (MBC) patients.
苯達(dá)莫司汀，具有烷化劑和嘌呤類(lèi)似的雙相功能可以在轉(zhuǎn)移性乳腺癌（MBC）患者中發(fā)揮作用。
Results: The structure of the target compound was confirmed by MS,1H-NMR,IR analysis.The total yield of bendamustine was 33.5%.
結(jié)果:目標(biāo)化郃物的質(zhì)譜、核磁共振氫譜、紅外光譜均與文獻(xiàn)報(bào)道相吻郃;縂收率爲(wèi)33.;5%25。
This multicenter phase II trial defines the toxicity and activity of bendamustine in heavily pretreated patients.Patients and methods: Fifty-one patients were included.
本實(shí)騐爲(wèi)多中心II期臨牀試騐，旨在定義苯達(dá)莫司汀在治療失敗乳腺癌患者中的毒性和治療傚應(yīng)。
Conclusion : Single-agent bendamustine is an active treatment in patients with MBC independent of the previous treatment.The low toxicity profile favors its use as a single agent.
苯達(dá)莫司汀單葯治療MBC具有療傚，而其低毒性的特性支持其採(cǎi)用單葯治療。